SCHEMBL6480730

SCHEMBL6480730

CCC(=O)NN(CC)CC

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP2C9 P11712 1/20 0.36
TDP1 Q9NUW8 2/20 0.33
ALDH1A1 P00352 2/20 0.33
FFAR3 O14843 1/20 0.33
LMNA P02545 2/20 0.32
MAPT P10636 1/20 0.32
PKM P14618 1/20 0.32
MAPK1 P28482 1/20 0.32
CCR6 P51684 1/20 0.32
MCL1 Q07820 1/20 0.32
ATM Q13315 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
APOBEC3G Q9HC16 1/20 0.32
KDM7A Q6ZMT4 1/20 0.31
PHF8 Q9UPP1 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27876260 0.81 KDM4E (0.39) L3MBTL1KDM4EKDM7APHF8KDM2A
SCHEMBL7622688 0.79 KDM4E (0.38) L3MBTL1KDM4ETDP1ALDH1A1LMNA
SCHEMBL4915510 0.79 KDM4E (0.38) L3MBTL1KDM4E
SCHEMBL7522493 0.79 HDAC3 (0.50) L3MBTL1KDM4EMEN1KMT2AALDH1A1
Palmitic Acid SCHEMBL28160875 0.79 GPR84 (0.59) MEN1KMT2ACYP2C9TDP1ALDH1A1
SCHEMBL11063771 0.77 MEN1 (0.36) MEN1KMT2ACYP2C9MAPT
SCHEMBL27891550 0.77 CA12 (0.46) KDM4EMEN1KMT2AALDH1A1MAPT
SCHEMBL27656889 0.77 KDM4E (0.37) L3MBTL1KDM4E
SCHEMBL11224794 0.77 MEN1 (0.43) KDM4EMEN1KMT2ACYP2C9TDP1
SCHEMBL28204394 0.75 TSHR (0.39) L3MBTL1KDM4EMEN1KMT2ACYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102796160-A 17ss-hsd1 and sts inhibitors SOLVAY PHARM GMBH 2012-11-28 CN claimed
CN-101189251-B 17 beta-HSD 1 and STS inhibitors SOLVAY PHARM BV 2012-09-12 CN claimed
CN-102617389-A Synthetic method of N, N-diethyl-3-propionylaminoaniline ZHEJIANG RUNTU CO LTD 2012-08-01 CN claimed
CN-101448843-B Imidazolothiazole compounds for the treatment of disease AMBIT BIOSCIENCES CORP 2012-05-09 CN claimed
EP-0794827-B1 NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF AMERSHAM BIOSCIENCES AB (SE) 2002-07-10 EP claimed
CN-1293031-A Composition for treating hair and scalp containing dandruff removing agent and acrylic acid terpolymer OREAL (FR) 2001-05-02 CN claimed
CN-1292260-A Detergent composition made from keratin material OREAL (FR) 2001-04-25 CN claimed
US-6090252-A NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY PHARMACIA BIOTECH AB (SE) 2000-07-18 US claimed
EP-0794827-A1 NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF Pharmacia Biotech AB (SE) 1997-09-17 EP claimed
WO-1996016724-A1 NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF PHARMACIA BIOTECH AB (SE) 1996-06-06 WO claimed
US-10758538-B2 Heat shock protein binding compounds, compositions, and methods for making and using same MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2020-09-01 US disclosed
US-20190038626-A1 HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME MEMORIAL SLOAN-KETTERING CANCER CENTER 2019-02-07 US disclosed
US-10052325-B2 Heat shock protein binding compounds, compositions, and methods for making and using same MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2018-08-21 US disclosed
CN-105745272-B Aqueous emulsion surface treatment agent 大金工业株式会社 2018-07-03 CN disclosed
CN-105764980-B Surface conditioning agent 大金工业株式会社 2017-08-08 CN disclosed
CN-1422143-A Leave-in hair cosmetic compositions for enhancing volume PROCTER & GAMBLE (US) 2003-06-04 CN disclosed
EP-0794827-B1 NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF AMERSHAM BIOSCIENCES AB (SE) 2002-07-10 EP disclosed
US-6090252-A NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY PHARMACIA BIOTECH AB (SE) 2000-07-18 US disclosed
EP-0794827-A1 NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF Pharmacia Biotech AB (SE) 1997-09-17 EP disclosed
WO-1996016724-A1 NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF PHARMACIA BIOTECH AB (SE) 1996-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10758538-B2 Heat shock protein binding compounds, compositions, and methods for making and using same HSPBP1, HSF1, HSPA2 L3MBTL1 1584/4885KDM4E 3776/4885MEN1 2935/4885
US-20190038626-A1 HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME HSPBP1, HSF1, HSPA2 L3MBTL1 1584/4885KDM4E 3776/4885MEN1 2935/4885
US-10052325-B2 Heat shock protein binding compounds, compositions, and methods for making and using same HSPBP1, HSF1, HSPA2 L3MBTL1 1584/4885KDM4E 3776/4885MEN1 2935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.